Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Added value of ranitidine in paclitaxel premedication
2017-003535-11Phase 4Active
- Sponsor
- Erasmus MC
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ranitidine in Paclitaxel Hypersensitivity Reaction (2 arms), sponsored by Erasmus MC. Primary endpoint: Incidence of clinically relevant paclitaxel-induced hypersensitivity reactions (grade ≥3). Started Jun 2018; status: active.
02
Drugs
ranitidine
03
Conditions
Paclitaxel Hypersensitivity Reaction
Beyond the preview
Go deeper on 2017-003535-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003535-11.